SpyGlass Pharma, Inc.
SGP Nasdaq
SEC CIK 1778922
Follow SpyGlass Pharma
Weekly email: filings, results
Net income
−$24.3M
−147.1% vs same quarter last year
EPS, diluted
−$0.73
+83.9% vs same quarter last year
Operating cash flow
−$16M
−81.2% vs same quarter last year
Operating income
−$26.2M
−136.4% vs same quarter last year
Source: SEC XBRL filings · latest filing